Epilepsy is a common neurological disorder. Despite a broad range of commonly used
antiepileptic drugs, approximately 30% of patients with epilepsy have drug resistance or …

Eslicarbazepine acetate is a new anti-epileptic drug belonging to the dibenzazepine
carboxamide family that is currently approved as adjunctive therapy and monotherapy for …

Background: Epilepsy is a neurological condition with an increased probability of seizure
occurrence through time. Although many anti-epileptic drugs (AEDs) exist, they fail to treat …

Eslicarbazepine acetate (ESL) is a once-daily antiepileptic drug that is approved as
adjunctive therapy in adults with focal-onset seizures. Following oral administration, ESL is …

Introduction: Up to 30% of the patients diagnosed with epilepsy will continue suffering from
seizures despite treatment with antiepileptic drugs, either in monotherapy or polytherapy …

Introduction: Eslicarbazepine acetate (ESL) is a novel antiepileptic drug registered as the
adjunctive treatment of partial-onset seizures in adults. As a third-generation medication …

Eslicarbazepine acetate (ESL) is a new antiepileptic drug whose mechanism of action is
blockade of the voltage-gated sodium channel (VGSC). However, in respect to …

Partial epilepsy comprises simple partial seizures, complex partial seizures, and secondarily
generalized seizures, and covers more than 60% of patients with epilepsy. Antiepileptic …

Introduction: Eslicarbazepine acetate (ESL) is a third-generation antiepileptic drug (AED)
approved for adjunctive treatment in adults, children, and adolescents with focal-onset …

Eslicarbazepine acetate (Aptiom®) is a once-daily, orally administered antiepileptic drug
(AED) approved previously in the EU, USA and several other countries for use as adjunctive …